(1) Laboratories
shall submit clinical material from cases identified with organisms listed in
Subsection R386-702-5(3)
to the Utah Department of Health and Human Services, Utah Public Health
Laboratory (UPHL) within three working days of identification.
(a) Clinical material is defined as:
(i) A clinical isolate containing the
organism for which submission of material is required; or
(ii) If an isolate is not available, material
containing the organism for which submission of material is required, in the
following order of preference:
(A) a patient
specimen;
(B) nucleic acid;
or
(C) other laboratory
material.
(2) Laboratories submitting clinical material
from cases identified with organisms designated by UPHL as potential
bioterrorism agents shall first notify UPHL via telephone immediately during
business hours at (801) 965-2400, or after hours at (801) 560-6586.
(3) Organisms mandated for standard clinical
submission include:
(a) antibiotic resistant
organisms from any clinical specimen that meet the following criteria:
(i) resistant to a carbapenem in:
(A) Acinetobacter species;
(B) Enterobacter species;
(C) Escherichia coli;
(D) Klebsiella species; or
(E) Pseudomonas aeruginosa;
(ii) resistant to vancomycin in
Staphylococcus aureus (VRSA);
(iii)
demonstrated carbapenemase production in:
(A)
Acinetobacter species;
(B)
Enterobacter species;
(C)
Escherichia coli;
(D) Klebsiella
species;
(E) any other
Enterobacteriaceae species; or
(F)
Pseudomonas aeruginosa;
(b) Campylobacter species;
(c) Candida auris or Candida haemulonii from
any body site;
(d) Corynebacterium
diphtheriae;
(e) Shiga
toxin-producing Escherichia coli (STEC), including enrichment or MacConkey
broths that tested positive by any method for Shiga toxin;
(f) Haemophilus influenzae, from normally
sterile sites;
(g) influenza A
virus, unsubtypeable;
(h) influenza
virus (hospitalized cases only);
(i) Legionella species;
(j) Listeria monocytogenes;
(k) measles (rubeola) virus;
(l) Mycobacterium tuberculosis
complex;
(m) Neisseria
meningitidis, from normally sterile sites;
(n) Salmonella species;
(o) SARS-CoV-2 NAAT-positive
samples;
(p) Shigella
species;
(q) Vibrio
species;
(r) West Nile
virus;
(s) Yersinia
species;
(t) Zika virus;
and
(u) any organism implicated in
an outbreak when instructed by authorized local or state health department
personnel.
(v) mandatory submission
requirements may be temporarily suspended or modified by the
Department.
(4) Organisms
mandated for bioterrorism clinical submission include:
(a) Bacillus anthracis;
(b) Brucella species;
(c) Clostridium botulinum;
(d) Francisella tularensis; and
(e) Yersinia pestis.
(5) Submission of clinical material does not
replace the requirement for laboratories to report the event to public health
as defined in Sections
R386-702-6 and
R386-702-7.
(6) For additional information on this
process, contact UPHL at (801) 965-2400.
